Syndax Pharmaceuticals
Clinical trials sponsored by Syndax Pharmaceuticals, explained in plain language.
A biopharmaceutical company developing cancer therapies, including treatments for leukemia and other malignancies.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug combo aims to beat tough leukemia
Disease control Recruiting nowThis phase 3 trial tests whether adding the drug revumenib to standard intensive chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) that has a specific genetic change (NPM1 mutation). About 468 participants will receive either revumenib or a placebo along…
Phase: PHASE3 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New hope for GVHD patients who failed other treatments
Disease control Recruiting nowThis study tests a drug called axatilimab in people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant where donor cells attack the patient's body. Participants must have tried at least two other treatments without success. The goal is to …
Phase: PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough leukemias: experimental pill targets genetic weakness
Disease control Recruiting nowThis study tests an oral drug called revumenib in people with certain types of leukemia that have relapsed or not responded to standard therapy. The trial has two parts: first, finding the best dose, then testing that dose in four groups based on leukemia type. About 447 particip…
Phase: PHASE1, PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC